Joseph Michael Guenther Jr. MD
Breast, Surgical Oncology (Other than Breast)
Physician
Join to View Full Profile
20 Medical Village Dr Ste 254Edgewood, KY 41017
Phone+1 859-344-1600
Fax+1 859-344-0091
Are you Dr. Guenther?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Joseph Guenther Jr., MD is a general surgeon in Edgewood, Kentucky. He is currently licensed to practice medicine in Kentucky, Ohio, and California.
Education & Training
University of Cincinnati Medical Center/College of MedicineResidency, Surgery, 1987 - 1992
University of Michigan Medical SchoolClass of 1987
Certifications & Licensure
CA State Medical License 1992 - Present
OH State Medical License 2001 - 2027
KY State Medical License 2002 - 2026
American Board of Surgery Surgery
Publications & Presentations
PubMed
- A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-GEP for SLNB) test demonstrates reduced numbe...J Michael Guenther, Andrew Ward, Brian J Martin, Mark Cripe, Rohit Sharma
World Journal of Surgical Oncology. 2025-01-03 - 5 citationsEndocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or...Cynthia X Ma, Vera J Suman, Souzan Sanati, Kiran Vij, Meenakshi Anurag
JAMA Oncology. 2024-03-01 - 4 citationsPresurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial.Seema A Khan, Xinlei Mi, Yanfei Xu, Luis Z Blanco Jr, Azza M Akasha
JAMA Surgery. 2023-12-01
Press Mentions
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma TestApril 3rd, 2025- Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024November 6th, 2024
